A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

Carcinoma, Thymic Clinical Trial

Official title:
An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

Status Completed

Clinical Trial Summary

This is a phase II, open-label, single-arm, multicenter study of the efficacy and safety of atezolizumab treatment in participants with advanced thymic carcinoma who failed prior systemic therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04321330
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Completed
Phase	Phase 2
Start date	August 7, 2020
Completion date	June 3, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05544929` - A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers	Phase 1
Not yet recruiting	`NCT04985357` - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Recruiting	`NCT05461430` - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Active, not recruiting	`NCT01306045` - Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies	Phase 2